Baxter Issues Recall Due to Particulate Matter - - BioPharm International

ADVERTISEMENT

Baxter Issues Recall Due to Particulate Matter


Baxter Healthcare Corp. has initiated a nationwide recall of more than 20,000 containers of Brevibloc Premixed Injection, esmolol hydrochloride in sodium chloride due to the presence of particulate matter.

According to FDA’s July 9 enforcement report, Baxter received complaints of discolored solution identified as subvisible particles of iron oxide that are agglomerating. Baxter issued the recall voluntarily on June 16, 2014.

The recall involved 2,500 mg/250 mL (10 mg/mL), 250 mL Single Use IntraVia container, packaged in 10 x 250 mL Single Use IntraVia containers per carton.

Source: FDA

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines

Click here